Seeking Alpha

Alp Bugra Basat

 
View as an RSS Feed
View Alp Bugra Basat's Comments BY TICKER:
Latest  |  Highest rated
  • More On The GlaxoSmithKline Shanghai Scandal [View article]
    Oooo yeah, made in China!!!
    Jun 11 03:04 PM | Likes Like |Link to Comment
  • Sarepta Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript) [View article]
    Ahahahaha :D I'll let Dr. Watson know. Funny.
    May 23 06:20 PM | Likes Like |Link to Comment
  • Invest In Greece Because The Turnaround Has Already Started [View article]
    I am really nervous right now. Because I am abroad and I couldn't buy any Greek stock so far. Just watching. Hope you already took your position.

    Best,
    Alp
    May 16 01:46 PM | Likes Like |Link to Comment
  • Invest In Greece Because The Turnaround Has Already Started [View article]
    I agree, but also any kind of real-estate in Greece would be a good investment. Turn around is soon.
    May 13 10:49 AM | 2 Likes Like |Link to Comment
  • ImmunoGen's Symbiotic Relationships Thru TAP Will Beef Up Its Stock Price [View article]
    I am long ADC. ADC is going to kick out classic anticancer antibodies. ADC can be Seattle genetics or Immunogen does not matter. In addition, ADC is tricky, since the drug-Ab linker is the key technology and the linker used in Kadcyla developed by Genentech. Just FYI.
    May 9 05:22 PM | Likes Like |Link to Comment
  • Titan Pharma Approaches Expected FDA Approval [View article]
    Oucchhhhhh!!!
    May 1 05:05 PM | Likes Like |Link to Comment
  • Verastem's Focal Adhesion Kinase Inhibitors And Their Great Potential [View article]
    Thank you for your comment. I have checked their web site [ http://bit.ly/11qylaJ ] but unfortunately i couln't find info in terms of their advisory board and their potential csc targets. Are you affiliated with that company? You can message me as well.
    Apr 20 08:35 AM | Likes Like |Link to Comment
  • Can Gilead Maintain Its Momentum? [View article]
    Yes Gilead is more like Amgen and Biogen. I am not talking or comparing Gilead to Vivus. I mentioned about articles written before.
    Apr 14 03:12 PM | Likes Like |Link to Comment
  • New Battleground Emerges For Dendreon Bulls And Bears [View article]
    People will watch ad, and they will ask their oncologist about it. The opinion of oncologist will be of great value for the patients since majority of the patients cannot understand such an advanced type of cancer treatment. Thus, opinions of oncologists will determine the Provenge sales.
    Apr 11 06:37 PM | 1 Like Like |Link to Comment
  • High Risk Trading With Dendreon [View article]
    I warned everybody here... They are NOT professional investors. One member of the EFS so called investment:

    http://linkd.in/16NqtDg
    http://bit.ly/XuNyrP_~01b42e05451e5b8315/

    english lang. undergrad...

    spread the word and inform SA editors please. SA should have a credibility...
    Apr 11 03:04 PM | Likes Like |Link to Comment
  • High Risk Trading With Dendreon [View article]
    I warned everybody here... They are NOT professional investors. One member of the EFS so called investment:

    http://linkd.in/16NqtDg

    english lang. undergrad...

    spread the word and inform SA editors please. SA should have a credibility...
    Apr 11 03:03 PM | 1 Like Like |Link to Comment
  • Nokia: Not Enough Luck With The Lumia [View article]
    @Oldwarrior I say, just don't take those articles too serious...
    Apr 11 05:38 AM | Likes Like |Link to Comment
  • Can Gilead Maintain Its Momentum? [View article]
    One really should stop them:

    http://seekingalpha.co...

    Vivus now: 11.25

    No more words...
    Apr 10 05:28 PM | Likes Like |Link to Comment
  • Has Smith & Nephew Found Its Next Target? [View article]
    VSTM's valuation is not only about ovary cancer, they claim that their approach can "cure" solid tumors which contain cancer stem cell. They choose to start with ovary cancer because there is no effective treatment for that, so they can get an accelerated approval for it. Their target is all solid tumors so market cap for VSTM is well above your calculations, if they succeed.
    Apr 4 12:37 PM | Likes Like |Link to Comment
  • Sarepta Therapeutics' Eteplirsen Trial: A Closer Look Reveals Clinical Uncertainty [View article]
    GSK/Prosensa is now running a phase 3 clinical trial for their Drisapersen (another version of etaplirsen). So a phase 3 requirement for Etaplirsen won't be surprise to me. But I think etaplirsen will get an AA given its safe side effect profile.
    Mar 31 01:54 PM | Likes Like |Link to Comment
COMMENTS STATS
50 Comments
17 Likes